Management Team

Laura K. Shawver, Ph.D. has served as our Chief Executive Officer and a member of our board of directors since June 2002. In addition, she served as our President until October 2007. Prior to joining us, Dr. Shawver was the President of SUGEN, Inc. from October 2000 to May 2002, after holding various positions there since June 1992. SUGEN, Inc., a biopharmaceutical company focused on the discovery and development of small molecule drugs which target specific cellular signal transduction pathways, was acquired by Pharmacia Corporation in 1999. Prior to her employment at SUGEN, Inc., Dr. Shawver was employed at Berlex Biosciences, formerly known as Triton Biosciences, from August 1989 to June 1992. She currently serves as a director of Antipodean Pharmaceuticals, a privately held clinical-stage pharmaceutical company. Dr. Shawver received a Ph.D. degree in Pharmacology and a B.S. degree in Microbiology, both from the University of Iowa. [CLOSE BIO]

Julie Cherrington, Ph.D., is an executive officer and has served as our President since October 2007. From May 2004 to October 2007, Dr. Cherrington served as our Executive Vice President, Research and Development. From November 2003 to October 2006, Dr. Cherrington also served as the President of our wholly-owned subsidiary, Phenomix Australia, Pty Ltd. Prior to joining us, Dr. Cherrington was employed with SUGEN, Inc. from October 1998 to October 2003, most recently serving as its Vice President, Preclinical Research and Exploratory Development. Prior to her tenure at SUGEN, Inc., Dr. Cherrington held various positions of increasing responsibility at Gilead Sciences, Inc., culminating in her position as director of virology. Dr. Cherrington is a member of the board of directors of Chemgenex Pharmaceuticals Limited, a publicly traded pharmaceutical development company. Dr. Cherrington received a Ph.D. degree in Microbiology from the University of Minnesota, with Ph.D. thesis research conducted at Stanford University, and an M.S. degree in Microbiology and a B.S. degree in Biology both from the University of California, Davis. [CLOSE BIO]

Christopher L. Burnley, is an executive officer and has served as our Executive Vice President and Chief Operating Officer since September 2007. From May 2003 to September 2007, Mr. Burnley served as our Chief Business Officer. From May 1996 to December 2002, Mr. Burnley was employed in various capacities by The Monsanto Company, a multinational agricultural biotechnology corporation, where he most recently served as the Vice President, Business and Operations, of Monsanto's Genomics Unit. From May 1987 to April 1996 Mr. Burnley was employed by Boston Consulting Group, a multinational corporate strategy consulting firm. Mr. Burnley received an M.B.A. degree from the Harvard Business School and B.S. degrees in Economics and Political Science from Southern Methodist University. [CLOSE BIO]

Brian Baker, C.P.A. has served as our Vice President of Finance since September 2007. Mr. Baker joined Phenomix in April 2006 as Director of Finance. From February 2006 to March 2006, Mr. Baker served as the Corporate Controller at Sequenom, a company that manufactures genetic analysis products. Mr. Baker was with Cengent Therapeutics, a biotechnology company, from April 2000 to January 2006, where he was Corporate Controller and held other senior finance positions. Between September 1996 to April 2000, Mr. Baker was a Senior Audit Staff Member at PricewaterhouseCoopers. Mr. Baker maintains an active license to practice as a Certified Public Accountant in California with a B.S. degree in accounting and a M.S. degree in information systems, both from San Diego State University.. [CLOSE BIO]

Angela Birchler, Ph.D. has served as our Vice President, CMC since April 2008. Prior to joining Phenomix, Dr. Birchler served as Vice President, Manufacturing for Kanisa Pharmaceuticals, Inc., a biopharmaceutical company which she joined in January 2006. Before that, Dr. Birchler held positions with increasing responsibilities in pharmaceutical development and commercial manufacturing at Pfizer from 2001 to 2005, Warner-Lambert from 1998 to 2001 and Agouron Pharmaceuticals from 1995 to 1998. Dr. Birchler received a Ph.D. in organic chemistry from Emory University. [CLOSE BIO]

David Campbell, Ph.D. has served as our Vice President, Drug Discovery and Preclinical Sciences since January 2005. From May 2003 to January 2005, Dr. Campbell served as our Vice President, Drug Discovery. Prior to joining Phenomix, Dr. Campbell served as the Senior Vice President Chemical Sciences of ActivX Biosciences, Inc., a biopharmaceutical company from January 2003 until May 2003. Prior to his tenure at ActivX, Dr. Campbell was the Director of Discovery Chemistry at Bayer, and held positions of increasing responsibility at Affymax/Glaxo-Wellcome, culminating in his position as Director of Discovery Chemistry. Dr. Campbell received a Ph.D. and M.S. degrees in Chemistry from Cornell University and a B.S. degree in Chemistry from Harvey Mudd College. [CLOSE BIO]

Hans-Peter Guler, M.D. has served as our Vice President, Clinical Development since August 2004. Prior to joining Phenomix, Dr. Guler served as Vice President, Clinical Sciences of Regeneron Pharmaceuticals, Inc., a biopharmaceutical company which he joined in April 1998. Before that, Dr. Guler held positions with increasing responsibilities in various therapeutic indications in clinical development at Chiron Corp. from 1994 to 1998 and at Ciba-Geigy from 1989 to 1994. Dr. Guler received an M.D. degree from the University of Zurich. [CLOSE BIO]